Pfizer, Haleon

Why Pfizer sold its $3 billion stake in Haleon
Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each,
Pfizer Further Pares Haleon Stake With £2.5 Billion Sale
Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyAs E-Bikes Boom in NYC,
Pfizer Cuts Stake in Haleon PLC with $2.6 Billion Share Sale
Pfizer has reduced its stake in the British healthcare company Haleon PLC to 7.3% by selling £2.5 billion ($3 billion) worth of shares, according to a bookrunner for the sale. J.P. Morgan Securities PLC reported Wednesday that Pfizer Inc.
Pfizer to sell $3 billion stake in Sensodyne maker Haleon
Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on Wednesday.
Pfizer Sells 700 Million Haleon Shares for $3.05 Billion
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer Has Sold 700M Haleon Shares
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
Pfizer going 'all in' on obesity drug development, CEO Bourla says
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...
GlobalData on MSN2d
Pfizer believes in the metaverse: will healthcare thaw the technology’s winter?
The metaverse hype is over, but developer Cassette Group has been working with Pfizer to realise its forgotten potential.
MercoPress2d
COVID-19 booster shots are better if specific brands are used
The third scenario, in which the booster dose was with the Pfizer vaccine, showed the highest percentages of effectiveness: 56.8% against symptomatic infections and 85.5% against severe cases.
FiercePharma2d
Novo's semaglutide among 2nd batch of drugs selected for IRA price negotiations
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
GSK, Pfizer RSV shots must warn about rare paralysis risk
Barré for every million doses given.
Pfizer (NYSE:PFE) Stock Price Down 0.8% on Analyst Downgrade
Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price fell 0.8% during trading on Thursday after UBS Group lowered their price target on the stock from $31.00 to $29.00. UBS Group currently has a ...
FiercePharma10d
RSV vaccines from Pfizer, GSK take another hit with new FDA warning mandate
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...